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1. ABSTRACT
The migration of leukocytes from intravascular locations to extravascular sites is 
essential to the immune responses. The initial attachment of leukocytes to the 
endothelium and the rolling step of the leukocyte extravasation cascade are mediated by 
selectins, a family of cell adhesion molecules on cell surfaces. All three selectins, P-, E- 
and L-selectins, are able to recognize glycoproteins and glycolipids containing the 
tetrasaccharide sialyl Lewis x (sLex, Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc). The 
biosynthesis of cell surface glycoconjugates involves specific glycosyltransferases 
utilizing nucleotide sugars as activated donors. The last step in the formation of sLex is 
the transfer of fucose from GDP-L-fucose to sialylated N-acetyllactosamine by α1,3-
fucosyltransferase VII. 
GDP-L-fucose is synthesized in the cytosol via two distinct pathways. The major, de 
novo pathway involves conversion of GDP-D-mannose to GDP-L-fucose by 
dehydration, epimerization and reduction reactions performed by two enzymes, GDP-
D-mannose-4,6-dehydratase (GMD) and GDP-4-keto-6-deoxy-D-mannose-3,5-
epimerase-4-reductase (FX). In the alternative salvage pathway free fucose is converted 
to GDP-L-fucose by L-fucokinase and GDP-L-fucose pyrophosphorylase. The GDP-
fucose transporter translocates GDP-L-fucose from the cytosol to the Golgi for the 
corresponding fucosyltransferase. 
This thesis describes molecular cloning and expression of murine L-fucokinase and 
GDP-L-fucose pyrophosphorylase involved in the synthesis of GDP-fucose via the 
salvage pathway. The gene expression levels of these enzymes were found to be 
relatively high in various tissues; the mRNA levels were highest in brain, ovary and 
testis. This study also describes molecular cloning of rat fucosyltransferase VII (FUT7) 
and its expression as a functional enzyme. Gene expression levels of GDP-L-fucose 
synthesizing enzymes, GDP-fucose transporter and FUT7 were determined in inflamed 
tissues as well as cancer cells. Our results revealed a clear upregulation of GMD, FX, 
GDP-fucose transporter and FUT7 in inflamed tissues and in cancer cells. On the 
contrary, the GDP-L-fucose salvage pathway was found to be irrelevant in 
inflammation and in tumorigenesis. Furthermore, our results indicated the 
transcriptional coregulation of Golgi transporters involved in the synthesis of sulfo 
sLex, i.e. CMP-sialic acid, GDP-fucose and 3’phosphoadenosine 5’-phosphosulfate 
transporters, in inflammation. 
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2. REVIEW OF THE LITERATURE 
2.1 The role of fucosylated glycans in humans 
2.1.1 Fucose in human glycan structures 
Carbohydrate chains are linked to proteins and lipids on cell surfaces. Protein 
glycosylation encompasses N-glycans, O-glycans, glycosaminoglycans and 
glycosylphosphatidylinositol (GPI) anchor proteins. N-glycans are linked to asparagine 
residues of proteins, specifically within the consensus sequence asparagine-X-
serine/threonine (Asn-X-Ser/Thr), where X can be any amino acid residue except for 
proline (Schachter, 2000; Yan & Lennarz, 2005). O-glycans are linked to a subset of 
serine or threonine residues. Glycosaminoglycans are also attached to serine and 
threonine, however, they are linear and produced by different biosynthetic pathways, 
and are often highly sulfated (Esko & Selleck, 2002). GPI is a complex glycolipid that 
acts as a membrane anchor for many cell surface proteins (Kinoshita & Inoue, 2000).
N-glycans are constructed in sequential manner by specific glycosyltransferase and 
glycosidase enzymes in the endoplasmic reticulum (ER) and Golgi apparatus. O-
glycans are synthesized by glycosyltransferases in Golgi and in the cytoplasm. 
Glycosyltransferases synthesize glycan chains, whereas glycosidases hydrolyse 
specific glycan linkages. The expression of mammalian glycans is regulated at both 
postranscriptional and postranslational levels (Ohtsubo & Marth, 2006). Some 
glycosyltransferases and glycosidases must be glycosylated themselves to be active. 
Subsequently, they may be regulated through phosphorylation of their cytoplasmic 
tails, which may lead to differential substrate access and intracellular trafficking. 
Hence, the intracellular location of glycosyltransferases and glycosidases can be an 
effective regulator of glycan formation by controlling access to acceptor substrates. 
Loss of some chaperones and multiprotein complexes alters glycosyltransferase 
trafficking between the ER and Golgi (Foulquier et al., 2006; Ju & Cummings, 2005; 
Wu et al., 2004).  
Each class of glycans share a limited number of core structures to which the specific 
saccharide groups are attached. These terminal groups are usually responsible for the 
biological functions of carbohydrates. Vertebrate N-glycan diversification in the Golgi 
generates three N-glycan subtypes: high mannose, hybrid and complex types that share 
the same core structure Man3GlcNAc2-Asn. Most secreted and cell surface N-glycans 
are of the complex type containing a various number of galactose (Gal), N-
acetylglucosamine (GlcNAc), sialic acid (SA) and fucose (Fuc) residues linked to N-
glycan core structure. Core fucosylation is a common structural feature among N-
glycans. Many vertebrate N-glycans are modified by fucosyltransferase that adds Fuc 
via an α1-6 linkage to the GlcNAc residue that is linked to asparagine (Wilson et al., 
1976). All mucin-type O-glycan structures contain a GalNAcα-residue linked to 
Ser/Thr. Most mucin-type O-glycans contain the core 1 subtype structure formed by 
the addition of galactose via a β1-3 linkage to the GalNAc by Core 1 β1-3 
galactosyltransferase (Core 1 GalT). Core 2-type is generated by addition of GlcNAc 
to the GalNAc of the core 1 structure via a β1-6 linkage. Hence, the production of core 
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2 O-glycans requires the core 1 structure as a substrate and the activity of Core 2 β1-6 
glucosaminyltransferase (Core 2 GlcNAcT). There are also several other O-glycan 
core subtypes, which results in more complex O-glycan diversification. 
Figure 1. Examples of the common glycan structures with different fucosylation. 
a) α1,6-fucosylation is involved in the core structure of vertebrate N-glycans. b) H-antigen is 
an α1,2-fucosylated structure. c) α1,3-fucosylated Lewis x represents type 2 structure. d) α1,4-
fucosylated Lewis a is a type 1 structure.
Fucose has two isomers, L and D, of which the D isomer is rare and not found in 
mammals. L-fucose (6-deoxy-L-galactose) is an essential component of various 
mammalian glycan structures. It decorates N-and O-linked glycoproteins and 
glycolipids (Walz et al., 1990) or is covalently linked to some serine or threonine 
residues of proteins (Harris & Spellman, 1993). Fucose can be linked via α1,2-linkage 
to terminal Gal, α1,3- or α1,4- linkage to subterminal GlcNAc or via α1,6-linkage to 
the innermost GlcNAc as shown in Figure 1. 
Fucosylated glycoproteins and glycolipids can be present in cell membranes or 
secreted into biological fluids. Various functions in biological processes have been 
established for fucose residues (Becker & Lowe, 2003; Staudacher et al., 1999). ABO 
blood group antigens are α1,2-fucosylated glycans (Greenwell, 1997; Lloyd, 2000). 
α1,3-and α1,4-fucosylated modifications are essential components of sialyl Lewis x 
(sLex)- and sialyl Lewis a (sLea)- type glycans, respectively, which have roles as 
selectin ligands in inflammation (Lowe, 1997). Fucosylated glycans also have 
important roles in fertilization (Johnston et al., 1998; Mori et al., 1998). The Lewis x 
(Lex) epitope, also known as  stage-specific embryonic antigen-1 (SSEA-1), is 
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expressed during early embryogenesis indicating the essential role of Lex in cell 
adhesion events in embryonal development (Bird & Kimber, 1984; Eggens et al., 
1989). O-fucose residues, i.e. fucose is directly linked to hydroxyl groups of serine and 
threonine residues, are present on EGF domains of the mammalian Notch receptors 
(Moloney et al., 2000b; Rampal et al., 2005). Notch receptors are a family of signaling 
transmembrane proteins with important roles in normal development of an organism, 
e.g neurogenesis, angiogenesis and lymphoid development (Artavanis-Tsakonas et al., 
1999; Halloran et al., 2000). Fucosylation is also involved in programmed cell death, 
i.e. apoptosis (Hiraishi et al., 1993; Russell et al., 1998; Winkler et al., 2004). 
Figure 2. Leukocyte extravasation cascade. The first step involves the reversible binding of 
leukocyte to vascular endothelium through interactions between selectins and their 
carbohydrate ligands, such as sLex. This leads leukocyte to roll along the endothelium and to 
sense activating factors, such as chemokines. Leukocyte integrins (LFA-1) are activated and 
they bind to their counterreceptors (ICAM-1) on endothelium, which leads to firm adhesion 
and crossing the endothelial wall. Leukocyte squeezes between endothelial cells and penetrates 
the basement membrane leading to diapedesis. Finally, the leukocyte migrates through the 
tissue along the concentration gradient of chemokines secreted by cells at the site of 
inflammation. 
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2.1.2 Fucosylated glycans in leukocyte trafficking 
The migration of leukocytes from intravascular locations to extravascular sites is an 
essential component of the the innate and adaptive immune responses. The traffic of 
leukocytes from blood vessels into the surrounding tissues is termed extravasation 
(Figure 2). The first step in the extravasation cascade involves a transient adhesive 
contact between leukocytes and the vascular endothelium mediated by selectins, a 
family of cell-surface adhesion molecules of leukocytes and activated endothelial cells 
(Lowe, 1997; Varki, 1997). The adhesion of selectins to their glycosylated counter-
receptors, such as sLex, is weak and reversible allowing circulating leukocytes to roll 
along the endothelium (Etzioni et al., 1999; Vestweber & Blanks, 2000). Binding of 
leukocytes to the endothelium takes place under dynamic conditions due to blood 
flow. Recent studies have revealed that this binding occurs more tightly when blood 
flow is increased (Marshall et al., 2003; Yago et al., 2004). Rolling brings leukocytes 
into close contact with the endothelium, which leads the endothelial-bound 
chemokines to bind to their respective chemokine receptors on leukocytes. This 
phenomenon activates leukocyte-specific β2-integrins, such as LFA-1, to bind to their 
counter-receptors on endothelial cells leading to the tight binding of leukocytes to 
endothelium (Arnaout, 1990; Imhof & Aurrand-Lions, 2004). The counter-receptors of 
β2-integrins, such as ICAM-1 or ICAM-2, belong to the immunoglobulin gene 
superfamily. After tight binding the leukocytes diapedese between endothelial cells 
and finally migrate through the endothelial cell layer and the underlying basal 
membrane into tissue to participate in the inflammatory reaction. 
Selectins are a family of C-type lectins which contain an N-terminal extracellular 
lectin domain followed by a domain homologous to epidermal growth factor and two 
to nine consensus repeats similar to sequences found in complement regulatory 
proteins. Each of these adhesion receptors is inserted into membranes via a 
hydrophobic transmembrane domain and possesses a short cytoplasmic tail. Selectins 
have the ability to recognize and bind to specific carbohydrate determinants on 
selectin ligands in a calcium-dependent manner (Vestweber & Blanks, 1999). The 
selectin family consists of three proteins: L-, P-and E-selectins. P-selectin, the largest 
selectin of size 140 kDa, is the predominant selectin involved in leukocyte rolling on 
acutely inflamed endothelial cells in vivo (Ley et al., 1995). P-selectin is stored in the 
α-granules of platelets (Berman et al., 1986; Stenberg et al., 1985) and in secretory 
granules called Weibel-Palade bodies of resting endothelial cells (Bonfanti et al., 
1989; McEver et al., 1989). As endothelium is activated by histamine or platelets 
activated by thrombin, P-selectin is rapidly brought to the cell surface by 
degranulation of the compartments (Hamburger & McEver, 1990; Larsen et al., 1989; 
Moore & Thompson, 1992). Under conditions of chronic inflammatory stimulation, P-
selectin can be stably expressed on the cell surface (Pan et al., 1998; Yao et al., 1996). 
Except for skin microvessels, E-selectin is not constitutively expressed on resting 
vascular endothelium. Expression of E-selectin is induced after activation of 
endothelium by inflammatory cytokines, such as TNF-α, interleukin (IL)-1β and other 
stimuli, leading to the de novo transcription of E-selectin (Bevilacqua et al., 1987). L-
selectin, the smallest of the selectins, is expressed constitutively on circulating 
leukocytes (McEver, 1994; Rosen & Bertozzi, 1994). L-selectin is rapidly 
downregulated by sheddases upon cell activation by proteolytic cleavage near the cell 
surface (Smalley & Ley, 2005). The main function of L-selectin shedding from 
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lymphocytes is to prevent the re-entry of activated T cells to the secondary lymphoid 
organs (Galkina et al., 2003).
Leukocyte rolling participates in the recruitment of neutrophils, monocytes, 
eosinophils, and some effector T cells as well as dendritic cells to sites of acute and 
chronic inflammation (Sperandio, 2006). This requires the up-regulation of P- and E-
selectins and of endothelial L-selectin ligands on inflamed endothelium. Granulocytes 
and monocytes emigrate from the bloodstream to tissues in response to inflammatory 
stimuli. The counterreceptors for selectins in the weak adhesive contacts contain sLex 
and related carbohydrate structures. sLex, Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc, is a 
tetrasaccharide present in many glycoconjugates decorating proteins as well as lipids 
on cell surfaces. Several glycosyltransferases are involved in the biosynthesis of sLex; 
sialylation and fucosylation being the terminal glycosylation events (Lowe & Marth, 
2003). α2,3-sialyltransferases (ST3Gal) form an α2,3-sialic acid linkage to the 
terminal galactose of type 2 N-acetyllactosamine (LN). As the final step, α1,3-
fucosyltransferase (Fuc-T) transfers fucose from GDP-L-fucose to GlcNAc of α2,3-
sialylated LN. Sulfated isomers of sLex tetrasaccharide epitopes, being crucial in 
lymphocyte trafficking, are generated by a family of 6-O-sulfotransferases. They are 
able to sulfate GlcNAc, galactose or both, representing 6-sulfo sLex, 6’-sulfo sLex or 
6’,6-disulfo sLex, respectively (Hemmerich & Rosen, 2000). Structures of sLex and its 
sulfated derivatives are presented in Figure 3.  
   
Figure 3. Sialyl Lewis x and its sulfated derivatives. 
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P-selectin glycoprotein ligand-1 (PSGL-1) is a homodimeric sialomucin, i.e. a 
glycoprotein with multiple mucin-type O-glycans and repeating peptide motifs (Moore
et al., 1992). It is expressed on most leukocytes and is the best characterized ligand for 
selectins (McEver & Cummings, 1997). PSGL-1 has been characterized as a 
predominant ligand for P-selectin during inflammation (Xia et al., 2002; Yang et al., 
1999). It is also an important ligand for L-selectin (Guyer et al., 1996; Spertini et al., 
1996; Tu et al., 1996; Walcheck et al., 1996). A core 2 based O-glycan with sLex 
epitope as well as three tyrosine sulfates at the N-terminus of PSGL-1 are required for 
optimal P- and L-selectin recognition (Leppänen et al., 2000; Leppänen et al., 2003; 
McEver & Cummings, 1997). Studies with PSGL-1 deficient mice confirmed that L-
selectin mediated rolling during acute inflammation is mainly dependent on PSGL-1 
(Sperandio et al., 2003). Furthermore, the same study demonstrated L-selectin 
dependent rolling to occur mostly via secondary tethering, i.e. rolling occurred via 
interactions between flowing and adherent leukocytes (Sperandio et al., 2003). 
Contrary to acute inflammation, in chronic inflammation the L-selectin dependent 
rolling is mediated via endothelial L-selectin ligands (Rosen, 2004). PSGL-1 binds 
differently to E-selectin than it does to P- and L-selectin. Core 2, sialylated and 
fucosylated O-glycans are required for binding to E-selectin, but tyrosine sulfation is 
not required (Li et al., 1996;Goetz et al., 1997). An apparent divergence exists 
between P- and E-selectin in mediating leukocyte rolling on cytokine-activated 
endothelium. E-selectin is thought to be responsible for slow rolling interactions and 
possibly the initiation of firm adhesion (Jung & Ley, 1997; Kunkel & Ley, 1996). 
Circulating lymphocytes continuously patrol the body for foreign antigen by 
recirculating from blood into tissues and lymph and back to blood. Lymphocytes enter 
the secondary lymphoid organs at specialized endothelium on postcapillary venules in 
lymphoid tissue (von Andrian & Mempel, 2003). These high endothelial venules 
(HEVs) express specific vascular addressins called peripheral node addressins 
(PNAd), which bind subsets of circulating lymphocytes that express complementary 
homing receptor, L-selectin, on their surface (Rosen, 2004). The ligands of L-selectin 
are heavily O-glycosylated mucins, such as GlyCAM-1, CD34 and MAdCAM-1 
bearing sulfated sLex epitopes on core 1- and core 2-type O-glycans (Hemmerich et 
al., 1995; Rosen, 2004; Satomaa et al., 2002; van Zante & Rosen, 2003; Yeh et al., 
2001). One of the sulfated epitopes, 6-sulfo sLex has been shown to be important for 
L-selectin binding. Two GlcNac-6-O-sulfotransferases, GlcNAc6ST-1 and 
GlcNAc6ST-2 act co-operatively to synthesize 6-sulfo sLex epitopes on L-selectin 
ligands in HEV of lymph nodes in mice (Kawashima et al., 2005; Uchimura et al., 
2005). GlcNAc6ST-2 adds sulfate mainly to extended core 1 structures, whereas both 
GlcNAc6ST-1 and GlcNAc6ST-2 add sulfate to core 2 structures. Although sulfo sLex 
glycan epitopes are constitutively expressed in lymph node high endothelium, the 
expression is induced de novo in vascular endothelium at sites of inflammation by 
inflammatory mediators (Toppila et al., 1999; Toppila et al., 2000; Turunen et al., 
1995; van Zante & Rosen, 2003). Furthermore, previous studies indicate specific 
modifications of sLex and sulfo sLex in inflamed tissues of different organs 
(Renkonen et al., 2002).  
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2.1.3 Fucosylated glycans in cancer 
Cell surface carbohydrate determinants undergo dramatic changes during malignant 
transformation. Previous studies show that expression of sLex and sLea determinants 
is markedly enhanced in cancer cells (Kannagi, 1997; Majuri et al., 1995; Renkonen et 
al., 1997). Leukocyte responses to cancer have many parallels with inflammation, as 
the same determinants serve as ligands for selectins in inflammation and mediate 
hematogenous metastasis of cancers (Balkwill & Mantovani, 2001; Coussens & Werb, 
2002; Läubli et al., 2006). Leukocytes are considered to have antitumor roles but also 
to support tumor progression. Natural killer (NK) cells, playing an important role in 
innate immunity, are able to kill cancer cells without antigen stimulation (Ohyama et 
al., 2003). On the other hand, during early tumorigenesis inflammatory leukocytes can 
be efficient tumor promoters, producing chemokines, growth factors and cytokines 
required for tumor growth, angiogenesis, migration, and differentiation. Later in the 
tumorigenic process, neoplastic cells also divert inflammatory mechanisms such as 
selectin-ligand interactions to favour neoplastic spread and metastasis (Coussens & 
Werb, 2002). The interaction between tumor-associated carbohydrate antigens such as 
sLex or sLea expressed on cancer cells, and E- or P-selectin on endothelial cells of the 
target organ, is one of the first and crucial steps in the metastasis cascade (Aigner et 
al., 1998; Majuri et al., 1992). L-selectin has been proposed to facilitate the 
recruitment of inflammatory leukocytes to the sites of tumor cell emboli, i.e.
aggregated platelets and leukocytes, in microvasculature and thus support metastasis 
(Läubli et al., 2006). Hence, up-regulation of sLex and sLea can be associated with 
advanced tumor progression and poor prognosis (Inaba et al., 2003; Kannagi, 1997).  
Normal epithelial cells express various carbohydrate determinants, some of which 
have structures more complex than sLex and sLea. For example, 6-sulfo sLex and (2-
3, 2-6)-disialyl Lea determinants are further modified forms of sLex and sLea 
determinants (Kannagi, 2004). These complex determinants are present on non-
malignant colonic epithelial cells and mediate interaction of epithelial cells with 
mucosal mesenchymal cells expressing carbohydrate-binding molecules. Expression 
of genes responsible for the modification of 6-sulfo sLex and (2-3, 2-6)-disialyl Lea is 
impaired at the early stages of cancer initiation, which is proposed to occur mainly due 
to epigenetic silencing through promoter DNA methylation or histone deacetylation 
(Miyazaki et al., 2004). Later, in more advanced stages, cancer cells accumulate 
genetic abnormalities, and more malignant cancer cells with higher infiltrative and 
metastatic activities evolve due to accelerated expression of sLex and sLea 
determinants (Miyazaki et al., 2004).  
2.1.4 Fucosylated glycans in other diseases 
Altered glycosylation is involved in several diseases. Various autoimmune diseases 
and other human afflictions are conditions that result when the inflammatory response 
is uncontrolled, self-directed or in the wrong place at the wrong time. Cystic fibrosis 
(CF) is an autosomal genetic disease resulting in the accumulation of mucus in 
exocrine organs. CF mucins have high O-glycans content (Rhim et al., 2001; Scanlin 
& Glick, 1999); furthermore, comparison of CF mucins with mucins of healthy 
individuals, revealed significantly increased levels in sulfated and sialylated O-glycans 
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of CF mucins (Xia et al., 2005). Increased expression of fucosylated glycans on serum 
immunoglobulins have been detected in rheumatoid arthritis patients (Gornik et al., 
1999). Several pathological processes, such as reperfusion injury following ischemia, 
astma, and inflammatory skin diseases, are conditions that result from the excessive 
and uncontrolled recruitment of leukocytes (Boyman et al., 2007; Lefer et al., 1994; 
Toppila et al., 2000).  
Organ transplant rejection is caused by immune responses to alloantigens on the graft, 
proteins that vary from individual to individual within a species and are therefore 
perceived as foreign by the recipient. The pathogenesis of rejection results from the 
highly efficient extravasation of lymphocytes into the transplanted organ (Kirveskari
et al., 2000; Turunen et al., 1995).  
Deficiency of fucosylated glycans has been observed in a rare human disease, 
leukocyte adhesion deficiency type II (LAD II), which results from a defective GDP-
fucose transporter (Lubke et al., 2001). In this genetic disease patients suffer from 
recurrent infections, persistent leukocytosis and severe growth and mental retardation 
(Becker & Lowe, 1999; Etzioni et al., 1992).  
2.2 The synthesis of GDP-L-fucose 
Fucosylation requires a nucleotide-activated form of fucose, GDP-L-fucose, as a 
fucose donor for fucosyltransferases. GDP-L-fucose is synthesized in vivo via two 
different metabolic pathways, which both take place in cytosol. The pathways are 
shown in Figure 4. 
2.2.1 GDP-L-fucose synthesis via the de novo pathway 
The major, constitutively active, de novo pathway is evolutionarily conserved. It was 
first identified in bacteria (Ginsburg, 1960) and then described in plants (Liao & 
Barber, 1971), mammals (Overton & Serif, 1981), and invertebrates (Bulet et al., 
1984). The enzymes of the pathway have been cloned from several bacteria (Tonetti et 
al., 1998), plants (Bonin et al., 1997), and mammals (Reitman et al., 1980). 
Furthermore, the pathway has been characterized in silico in Drosophila melanogaster
(Roos et al., 2002).  
The de novo pathway involves conversion of GDP-α-D-mannose to GDP-β-L-fucose 
via three enzymatic reactions catalyzed by two enzymes, GDP-D-mannose-4,6-
dehydratase (gmds, GMD, EC 4.2.1.47) and GDP-4-keto-6-deoxy-D-mannose-3,5-
epimerase-4-reductase (Tsta3, in human designated as FX, EC 1.1.1.187) (Sullivan et 
al., 1998; Tonetti et al., 1996; Tonetti et al., 1998). In the first step, GMD converts 
GDP-D-mannose to an unstable intermediate, GDP-4-keto-6-deoxy-D-mannose, by a 
dehydration reaction. This enzyme reaction, oxidation of a hydroxyl group at C-4 of 
mannose to a keto group and reduction of a hydroxyl group at C-6 of mannose to a 
methyl residue, requires the cofactor nicotinamide adenine dinucleotide phosphate  
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Figure 4. The biosynthesis of GDP-L-fucose. De novo pathway, the constitutively active 
pathway, converts GDP-D-mannose to GDP-4-keto–6-deoxy-D-mannose via oxidation by 
GDP-mannose-4,6-dehydratase (GMD). The resulting intermediate is epimerized to GDP-4-
keto-6-deoxy galactose and further reduced to GDP-L-fucose by FX, an enzyme, which 
consists of 3,5-epimerase and 4-reductase. In the alternative salvage pathway, free fucose, 
obtained from extracellular sources or from lysosomal degradation of glycoconjugates, is 
phosphorylated by L-fucokinase to form L-fucose-1-phosphate, which is further converted to 
GDP-L-fucose by GDP-L-fucose pyrophosphorylase. GDP-fucose transporter translocates 
GDP-L-fucose to the Golgi, where it serves as a donor of fucose in a reaction catalyzed by a 
fucosyltransferase (Fuc-T). 
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(NADP+), which is reduced to NADPH during the reaction (Chang et al., 1985; Oths
et al., 1990; Sullivan et al., 1998). The enzyme cascade from GDP-D-mannose to 
GDP-L-fucose is inhibited by GDP-L-fucose as it is a potent competitive inhibitor of 
GMD (Bisso et al., 1999; Sturla et al., 1997). 
Dual functional epimerase-reductase enzyme FX converts GDP-4-keto-6-
deoxymannose to GDP-L-fucose (Chang et al., 1988; Tonetti et al., 1996). In the first 
FX reaction, GDP-4-keto-6-deoxy-D-mannose is epimerized at C-3 and C-5, which 
causes a change from D- to L-configuration and yields GDP-4-keto-6-deoxy-L-
galactose. The 4-reductase activity of the FX protein catalyzes a H+ transfer from the 
NADPH cofactor to a keto group yielding GDP-L-fucose and NADP+ (Menon et al., 
1999).  
GMD and FX transcripts are ubiquitously expressed in most human tissues (Sullivan
et al., 1998). A study of an induced mutation in the locus encoding mouse FX revealed 
the requirement for GDP-L-fucose in fertility, growth and development as well as in 
leukocyte adhesion (Smith et al., 2002). Fucosylated glycan deficiency has been 
corrected by dietary fucose supplementation, which restored the synthesis of GDP-L-
fucose through a normally quiescent salvage pathway (Smith et al., 2002).  
2.2.2 GDP-L-fucose salvage pathway 
The enzymes of the alternative, “salvage”, biosynthetic pathway of GDP-L-fucose 
synthesis, L-fucokinase (Fuk, EC 2.7.1.52) and GDP-L-fucose pyrophosphorylase 
(Fpgt, EC 2.7.7.30), were first discovered in pig liver in the 1960’s (Ishihara & Heath, 
1968a; Ishihara et al., 1968b). To date, L-fucokinase has been partially purified and 
characterized from porcine liver (Ishihara & Heath, 1968a) and thyroid gland (Kilker
et al., 1979), and purified to apparent homogeneity from pig kidney (Park et al., 1998). 
Furthermore, the human amino acid sequence has been identified (Hinderlich et al., 
2002). GDP-L-fucose pyrophosphorylase has been purified from porcine kidney and 
the corresponding gene has been cloned from man (Pastuszak et al., 1998). 
In the GDP-L-fucose salvage pathway, L-fucokinase synthesizes L-fucose-1-phosphate 
from L-fucose and ATP (Ishihara et al., 1968b; Park et al., 1998). L-fucokinase 
activity is feedback-inhibited by GDP-L-fucose (Park et al., 1998). The second step 
involves GDP-L-fucose pyrophosphorylase, also designated as fucose-1-phosphate 
guanylyltransferase, which catalyzes the formation of GDP-L-fucose from L-fucose-1-
phosphate and GTP (Ishihara & Heath, 1968a; Pastuszak et al., 1998). Free fucose for 
the salvage pathway is obtained from the diet, or in the case of cultured cells from 
culture medium, and is transported across the plasma membrane into the cytosol. 
Furthermore, free fucose can be obtained from intracellular degradation of 
glycoproteins and glycolipids in lysosomes by fucosidases (Michalski & Klein, 1999).  
Both Fuk (Miller et al., 2005; Park et al., 1998) and Fpgt activity (Pastuszak et al., 
1998) have been detected in various tissues indicating that salvage metabolism is a 
common phenomenon in eukaryotes. Previous studies indicate that fucokinase activity 
is regulated in response to stimulation of the brain by dopaminergic pathways and 
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exposure of aortic endothelial cells to nicotine (Hocher et al., 1993; Ricken et al., 
1990).  
2.3 Golgi transporters required for the synthesis of sulfo sialyl Lewis 
x glycan epitopes 
The biosynthesis of glycans is dependent on the activity of nucleotide sugar donor 
synthesis and transport to Golgi as well as the expression of specific 
glycosyltransferases. The activated nucleotide sugar is transported from cytosol to the 
Golgi via a donor-specific transporter. The nucleotide sugar transporter family, the 
solute carrier family SLC35, consists of at least 17 members in humans (Ishida & 
Kawakita, 2004). Nucleotide sugar transporters are 320-400 amino acid residues long 
and are structurally conserved hydrophobic multi-spanning transmembrane proteins 
(Gerardy-Schahn et al., 2001). They translocate nucleotide sugars from the cytosol, 
their site of synthesis, into the Golgi apparatus and the ER, where the activated sugars 
serve as substrates for a variety of glycosyltransferases.  
Lymphocyte homing is mediated by specific interactions between L-selectin on 
lymphocytes and sulfated carbohydrates restricted to HEVs in lymph nodes. Three 
modifications: sialylation, fucosylation and carbohydrate sulfation, are required for 
optimal L-selectin binding (Maly et al., 1996). The synthesis of sulfo sLex requires 
energy carrying donors, CMP-sialic acid (CMP-SA), GDP-L-fucose (GDP-L-Fuc) and 
3'-phosphoadenosine 5'-phosphosulfate (PAPS) for donation of SA, Fuc and sulfate, 
respectively. These sugar nucleotide donors are synthesized in the cytosol or nucleus 
and transported by specific transporters to the Golgi apparatus, where the 
corresponding transferases and acceptor molecules reside. CMP-SA is synthesized in 
the nucleus by CMP-SA synthase (Eckhardt et al., 1996; Lansdon et al., 2004) and is 
transported to the Golgi via CMP-SA transporter (SLC35A1) (Aoki et al., 2001; 
Eckhardt & Gerardy-Schahn, 1997; Eckhardt et al., 1999; Eckhardt et al., 1996).  
Sulfation of all macromolecules in higher organisms requires the high-energy donor 
PAPS, which is synthesized by the sequential actions of two cytoplasmic enzymes, 
ATP sulfurylase and APS kinase, and is subsequently transferred across the Golgi 
membrane for utilization by lumenal sulfotransferases (Ozeran et al., 1996). The 
specific PAPS transporter (SLC35B2) acts through an antiport mechanism with 
adenosine 3´, 5´ -bisphosphate as the returning ligand (Kamiyama et al., 2006; 
Kamiyama et al., 2003). 
GDP-fucose transporter (FUCT1, SLC35C1) is responsible for the uptake of GDP-L-
fucose by Golgi (Lubke et al., 2001; Luhn et al., 2001). GDP-fucose transporter is a 
protein with 10 predicted transmembrane domains spanning the Golgi membrane 
(Luhn et al., 2004). As with other sugar nucleotide transporters, the C- and N-terminal 
regions of GDP-fucose transporter are exposed to the cytosol. GDP-fucose transporter 
is a antiporter, which transports GDP-L-fucose from the cytosol into the Golgi lumen 
in exchange for guanidine monophosphate (GMP) (Puglielli & Hirschberg, 1999). 
LAD II, also known as a congenital disorder of glycosylation type IIc (CDG IIc) is 
caused by a defect in GDP-L-fucose transport. A missense mutation in the GDP-fucose 
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transporter leads to partially defective function and is responsible for the defective 
fucosylation in LAD II patients (Lubke et al., 2001; Luhn et al., 2001). In this very 
rare human disease patients suffer from recurrent infections and persistent 
leukocytosis due to the loss of particular selectin ligands (Becker & Lowe, 1999; 
Etzioni et al., 1992). In addition to immunodeficiency, LAD II patients show severe 
mental and growth retardation (Becker & Lowe, 1999; Wild et al., 2002). Fucosylation 
can be restored with oral fucose, indicating that salvage metabolism is responsible for 
the generation of GDP-L-fucose (Marquardt et al., 1999).  
2.4 Fucosyltransferases 
Fucose is transferred to acceptor oligosaccharides by various fucosyltransferases (Fuc-
T) via α1,2-, α1,3-, α1,4-, α1,6-linkages (Becker & Lowe, 2003). Examples of 
fucosylated structures are illustrated in Figure 1. Certain proteins can also be 
fucosylated directly by protein O-fucosyltransferase (O-Fuc-TI).  
α1,3-fucosyltransferases catalyze the transfer of fucose from GDP-L-fucose in an α1,3-
linkage to an appropriate acceptor substrate. This transfer is the final step in the 
synthesis of fucosylated glycoconjugates. Like other glycosyltransferases in the Golgi, 
fucosyltransferases consist of a lumenally oriented C-terminus with a large catalytic 
domain, a stem region, a single membrane spanning region and a short cytoplasmic N-
terminus. The N-terminal regions, i.e. cytoplasmic, transmembrane and stem regions, 
have the highest sequence heterogeneity (de Vries et al., 2001a). The N-terminal 
transmembrane domain has a role in the localization of this protein to the Golgi and in 
the retention of the enzyme. Secreted forms are produced by proteolysis in the Golgi 
apparatus at multiple protease sensitive sites within the stem region of the protein 
(Paulson & Colley, 1989). These soluble enzymes are responsible for the enzyme 
activities detected in milk and in body fluids such as serum or saliva (Mollicone et al., 
1990).  
Six human fucosyltransferase genes (FUT) encoding α1,3-fucosyltransferases have 
been cloned to date (de Vries et al., 2001a). FUT3 encodes the Lewis-type 
fucosyltransferase Fuc-TIII (Kukowska-Latallo et al., 1990) and FUT4 the myeloid-
type enzyme Fuc-TIV (Goelz et al., 1990; Kumar et al., 1991; Lowe et al., 1991). 
FUT5 encodes the enzyme Fuc-TV (Weston et al., 1992a) and FUT6 the plasma type 
enzyme Fuc-TVI (Koszdin & Bowen, 1992; Weston et al., 1992b). FUT7 encodes the 
leukocyte expressed Fuc-TVII (Natsuka et al., 1994; Sasaki et al., 1994) and FUT9 the 
Fuc-TIX (Kaneko et al., 1999). Furthermore, two additional putative α1,3-
fucosyltransferase genes, FUT10 and FUT11, have been identified in the human 
genome in silico by comparison with the fucosyltransferase sequences in the 
Drosophila melanogaster genome (Roos et al., 2002). The FUT3, FUT5 and FUT6
genes form a cluster on chromosome 19p13.3 (McCurley et al., 1995). Furthermore, 
the sequences of these genes are highly homologous to each other (Koszdin & Bowen, 
1992; Kukowska-Latallo et al., 1990; Weston et al., 1992a; Weston et al., 1992b)
suggesting a common ancestor (Oulmouden et al., 1997). FUT4, FUT7 and FUT9 are 
less similar to each other and to the former group.  
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In general, each glycosyltransferase recognizes only one type of sugar nucleotide. All 
fucosyltransferases utilize GDP-L-fucose as a L-fucose donor, hence, their specificities 
reside in the specific type of linkage formed and in the acceptors they recognize 
(Niemelä et al., 1998; Toivonen et al., 2002). Fuc-TIII catalyzes the formation of α1,3- 
and α1,4-linkages, being able to fucosylate both type 2 (Galβ1,4GlcNAc) and type 1 
(Galβ1,3GlcNAc) N-acetyllactosamines forming Lex and Lea, respectively 
(Kukowska-Latallo et al., 1990; Weston et al., 1992a). Nevertheless, Fuc-TIII strongly 
prefers type 1 lactosamine acceptors to type 2 acceptors (Kukowska-Latallo et al., 
1990; Weston et al., 1992a). The three homologous enzymes Fuc-TIII, Fuc-TV and 
Fuc-TVI act on both sialylated and non-sialylated acceptors (Koszdin & Bowen, 1992; 
Weston et al., 1992a; Weston et al., 1992b). Fuc-TV and Fuc-TVI prefer type 2 
lactosamine acceptors to type 1 acceptors. Fuc-TIV and Fuc-TIX act primarily on 
nonsialylated type 2 N-acetyllactosamine, which results in the formation of Lex 
(Britten et al., 1998; Kaneko et al., 1999; Niemelä et al., 1998). On the contrary, Fuc-
TVII prefers to fucosylate the α2,3-sialylated type 2 N-acetyllactosamine (Natsuka et 
al., 1994; Sasaki et al., 1994).  
α1,3-fucosyltransferases show complex tissue and cell type specific expression 
patterns, which vary during development and malignant transformation. Fuc-TIII is 
abundantly expressed in epithelial cells and gastrointestinal tissues, specifically 
stomach, jejunum and colon, but is not detected in brain, liver or peripheral blood 
leukocytes (Cameron et al., 1995). Fuc-TV is only minimally expressed in spleen, 
liver, colon and testis (Cameron et al., 1995). The tissue distribution of Fuc-TVI is 
similar to that of Fuc-TIII, except that Fuc-TVI is also expressed at high levels in liver 
and kidney (Cameron et al., 1995; Kaneko et al., 1999). Fuc-TIV is widely expressed 
in various tissues and cells (Gersten et al., 1995) whereas the expression of Fuc-TIX is 
restricted to brain, stomach, spleen and peripheral blood cells (Kaneko et al., 1999). 
Fuc-TIX is expressed as transcripts of different lengths in different tissues and 
developmental stages (Cailleau-Thomas et al., 2000; Kaneko et al., 1999). Fuc-TVII is 
expressed abundantly in leukocytes and in high endothelial cells of venules (Natsuka
et al., 1994; Sasaki et al., 1994). Fuc-TIV and Fuc-TVII complimentarily synthesize 
fucosylated cell surface epitopes recognized by selectins and thus are responsible for 
normal leukocyte trafficking and function (Natsuka et al., 1994; Niemelä et al., 1998; 
Smith et al., 1996; Weninger et al., 2000). The essential role of Fuc-TVII has been 
demonstrated in gene ablation experiments. Fuc-TVII-/- mice showed not only blood 
leukocytosis but also impaired lymphocyte homing and leukocyte extravasation to 
sites of inflammation (Maly et al., 1996; Smithson et al., 2001). In contrast to Fuc-
TVII-/- mice, studies with Fuc-TIV-/- mice demonstrated a minor significance for 
Fuc-TIV in neutrophil and lymphocyte recruitment (Homeister et al., 2001; Smithson
et al., 2001). Nevertheless, Fuc-TIV was indicated to be the major regulatory enzyme 
in the synthesis of selectin ligands in eosinophils (Satoh et al., 2005). 
α1,2-fucosyltransferases H and Se, encoded by FUT1 (Larsen et al., 1990) and FUT2, 
add fucose via α1,2-linkage to the terminal Gal of N-acetyllactosamine types 2 and 1, 
respectively, to make H antigens (Apoil et al., 2000). The H enzyme is responsible for 
the expression of H antigen in the red cell lineage and vascular endothelium, whereas 
the Se enzyme is responsible for the synthesis of H antigen in secretory epithelia 
(Kelly et al., 1995).  
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α1,6-fucosyltransferase Fuc-TVIII catalyzes the transfer of a fucose residue from 
GDP-L-fucose to the innermost GlcNAc residue of N-linked oligosaccharides in 
glycoproteins to form core fucosylation in mammals (Yanagidani et al., 1997). Fuc-
TVIII is widely distributed in mammalian tissues and human cancer cell lines (Struppe 
& Staudacher, 2000); Miyoshi et al., 1999). The catalytic mechanism of FucTVIII is 
distinct from α1,3/1,4-fucosyltransferases and is more similar to that for α1,2-
fucosyltransferases (Ihara et al., 2006; Takahashi et al., 2000). The common motifs 
between α1,2-and α1,6-fucosyltransferases and sequence similarity analysis suggest a 
common genetic origin for these families of enzymes (Breton et al., 1998; Oriol et al., 
1999).  
Protein O-fucosyltransferase I adds fucose directly to serine or threonine in EGF-like 
repeats of certain glycoproteins (Wang et al., 2001). The O-FUT1 gene sequence is 
highly conserved in mammals and is expressed in various mammalian tissues 
indicating that O-fucose modification has a significant roles in different contexts 
(Wang et al., 2001). O-fucose glycans on EGF-like repeats of several cell surface and 
secreted proteins play important roles in ligand-induced receptor signalling (Bruckner
et al., 2000; Harris & Spellman, 1993; Moloney et al., 2000a; Okajima et al., 2005). A 
short region associated with donor binding is conserved among α1,2-, α1,6- and 
protein O-fucosyltransferases, suggesting that O-FUT1 belongs to the same 
superfamily as α1,2-and α1,6-fucosyltransferases (Martinez-Duncker et al., 2003).  
The basic steps of the N-glycosylation pathway are evolutionally conserved in animals 
and plants. However, the structures of mature N-glycans differ between mammals and 
plants because of the major differences in the final steps of the biosynthetic pathways. 
While mature mammalian N-glycans are primarily of the complex type, mature plant 
N-glycans are mainly truncated Man3GlcNAc2-structures containing core α1,3-fucose 
and β1,2-xylose residues (Bondili et al., 2006). Comparing the porcine and human 
core α1,6-fucosyltransferases with the mung bean core α1,3-fucosyltransferase (Fuc-T 
C3), there are no significant sequence similarities despite similar substrate 
specificities. Subsequently, the amino acid sequence of cloned FucT C3 from mung 
beans showed only a low degree of overall homology with mammalian Lewis blood 
group α1,3/4-fucosyltransferases. However, a few highly conserved amino acid 
residues were identified between mammalian Lewis and plant core fucosyltransferases 
(Leiter et al., 1999). The plant glycan epitopes β1,2-xylose and core α1,3-fucose are 
not present in humans and therefore constitute epitopes for carbohydrate reactive 
antibodies, which represent a limitation for the therapeutical use of recombinant 
mammalian glycoproteins produced in transgenic plants (Strasser et al., 2004). Core 
α1,3-linked fucosylated glycans have also been identified in insects, but β1,2-xylose 
has not been detected in this class of organism. Instead, N-glycans of Drosophila 
melanogaster have been found to carry both core α1,3- and α1,6-linked fucose (Fabini
et al., 2001). Taken together, the substitution of the asparagine-linked GlcNAc by 
α1,3-linked fucose is a widespread feature of plant and insect glycoproteins.  
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3. AIMS OF THE PRESENT STUDY 
● to clone and express the murine enzymes of the GDP-L-fucose salvage pathway  
● to determine the expression levels of the salvage matabolism enzymes in different 
tissues 
● to clone and express rat fucosyltransferase VII 
● to compare the gene expression levels of GDP-L-fucose synthesizing enzymes, 
GDP-fucose transporter and Fuc-TVII in normal as well as inflamed tissue and in 
cancer cells 
● to investigate the possible transcriptional co-regulation of the different Golgi 
transporters required for the synthesis of sulfo sLex glycan epitopes  
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5. RESULTS AND DISCUSSION 
5.1 The GDP-L-fucose salvage pathway (I) 
5.1.1 Cloning of murine L-fucokinase and GDP-L-fucose pyrophosphorylase 
In the GDP-L-fucose salvage pathway free cytosolic fucose is phosphorylated by L-
fucokinase (Fuk) to form L-fucose-1-phosphate, which is further converted to GDP-L-
fucose in the reaction catalyzed by GDP-L-fucose pyrophosphorylase (Fpgt), as shown 
in Figure 3.  
A part of the putative murine L-fucokinase sequence was identified from mouse 
genomic sequence from the EMBL/Genbank/DDJB databases using the three known 
pig fucokinase peptide sequences (Park et al., 1998) as probes. The region 
corresponding to the putative L-fucokinase was cloned from mouse kidney cDNA and 
used as a query for further sequence database searches. An IMAGE clone containing 
the full coding sequence (CDS) of the putative L-fucokinase was identified and used 
for designing the primers for reverse transcription PCR (RT-PCR). Two cDNAs of 
sizes 3270 bp and 3057 bp were cloned from mouse kidney total RNA (Figure 3/I). 
These putative splice variants of L-fucokinase encoded proteins of 1090 amino acids 
(aa) and 1019 aa, respectively. Protein sequence variants were identical in the amino-
terminal end up to the splice area, as well as in the carboxy-terminal end after the 
alternative splice area, hence maintaining the same reading frame (Figure 2/I). While 
this work was under way, the gene encoding human L-fucokinase was reported 
(Hinderlich et al., 2002). A high degree of similarity exists between the human and 
mouse cDNAs, the human cDNA resembling the long splice variant of mouse L-
fucokinase at the splice area. 
The cloned human GDP-L-fucose pyrophosphorylase (Pastuszak et al., 1998) was 
used as a query in BLAST searches to find mouse expressed sequence tags (ESTs) 
corresponding to the putative Fpgt. By using the mouse EST as a probe, the 3’end of 
Fpgt was cloned by screening a mouse kidney cDNA library. The 5’end of the gene 
was resolved by the RACE-PCR method. The isolated cDNA consisted of 3480 bp 
predicting a protein of 591 aa (Figure 6/I). 
5.1.2 Expression of the enzymes involved in the GDP-L-fucose salvage pathway  
To determine the enzymatic activities of the proteins, the cloned genes were expressed 
in mammalian cells. The molecular masses of L-fucokinase proteins determined by 
Western blot analysis were 125 kDa and 115 kDa (Figure 4/I). The production of L-
fucose-1-phosphate from L-[3H]fucose and ATP was measured in order to determine 
the enzymatic activity of both L-fucokinase splice variants. The specific enzyme 
activity of the long splice variant was 598.5 pmol mg-1 h-1 in transfected COS-7 cells, 
whereas that of the short splice variant (13.7 pmol mg-1h-1) was at the same level as the 
mock control (11.4 pmolmg-1h-1) (Figure 5/I). 
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The product of the GDP-L-fucose pyrophosphorylase assay was identified by ion-pair 
reverse-phase high-performance liquid chromatography (HPLC). This method was 
developed for analysis of nucleotide sugars in our laboratory by Räbinä et al. (2001). 
Nucleotide sugars were first purified from cell lysate using solid-phase extraction 
(SPE) columns containing graphitized carbon. To remove impurities the samples were 
further treated with alkaline phosphatase, which degrades nucleotides but leaves 
nucleotide sugars intact. Purified negatively charged nucleotide sugars bound to ion-
pairing reagent TEAA and were retained in the HPLC column. They were eluted with 
a gradient of increasing acetonitrile concentration, and the synthesized nucleotide 
sugars were identified by comparison of retention times to those of nucleotide sugar 
standards. The analysis revealed a peak with the same retention time as the 
commercial GDP-L-fucose standard at 29.6 min (Figure 7/I). The peak was purified 
and subjected to further analysis by MALDI-TOF MS, which gave a single peak at 
588.08 m/z, being identical to the GDP-L-fucose control. 
5.1.3 Tissue distribution of L-fucokinase and GDP-L-fucose pyrophosphorylase  
Quantitative studies of fucose metabolism in HeLa cells demonstrate that over 90% of 
GDP-L-fucose is derived from the de novo pathway (Yurchenco & Atkinson, 1975). 
Nevertheless, as detected by quantitative real-time RT-PCR (qRT-PCR), various 
mouse tissues expressed considerably high mRNA levels of L-fucokinase and GDP-L-
fucose pyrophosphorylase. The mRNA expression of L-fucokinase was highest in 
brain, ovary and testis. Furthermore, significant expression could also be detected in 
kidney, liver and lung (Figure 8, panels A and B/I). A study by Park et al. (1998)
demonstrated high fucokinase activities in pig kidney, liver and brain. Moreover, a 
study of fucokinase activities in various rodent tissues by Miller et al. (2005) indicated 
that L-fucokinase activity was highest in brain. Fucokinase is upregulated in response 
to stimulation of the brain by dopaminenergic pathways and exposure of aortic 
endothelial cells to nicotine (Hocher et al., 1993; Ricken et al., 1990). Hence, L-
fucokinase may have a role in neuronal tissues. 
Gene expression of GDP-L-fucose pyrophosphorylase in various tissues resembles the 
gene expression pattern of L-fucokinase (Figure 8, panel C/I). High levels of GDP-L-
fucose pyrophosphorylase mRNA was detected in brain, testis, ovary and kidney. 
Expression levels were lower in liver, spleen, heart and kidney.  
The GDP-L-fucose salvage pathway is not universal and has been identified only in 
mammals (Park et al., 1998; Pastuszak et al., 1998). Salvage metabolism is used for 
GDP-L-fucose synthesis if the de novo pathway is blocked (Smith et al., 2002) or 
GDP-L-fucose import to the Golgi apparatus is impaired as in the case of the LAD II 
disorder (Lubke et al., 2001; Luhn et al., 2001). Nevertheless, GDP-L-fucose is 
synthesized via the salvage pathway only if extra fucose is supplied (Marquardt et al., 
1999). The distinct role of the GDP-L-fucose salvage pathway is still unelucidated, 
although the enzymes are relatively abundantly expressed in mammals. The specific 
salvage pathways also exist for other nucleotide sugars such as UDP-galactose, UDP-
glucuronic acid and UDP-N-acetylgalactosamine (Bulter & Elling, 1999). 
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5.2 Inflammation-induced transcriptional regulation of Golgi 
transporters involved in the synthesis of sulfo sLex glycan epitopes (II) 
Sulfo sLex epitopes are known to be induced de novo in vascular endothelium at sites 
of inflammation (Fukuda, 2002; Turunen et al., 1995; van Zante & Rosen, 2003). The 
decoration of N-acetyllactosamine, i.e. sialylation, fucosylation and sulfation, is 
carried out by specific transferases in the Golgi, to where the high-energy nucleotide 
derivates CMP-SA, GDP-L-Fuc and PAPS are transported from cytosol or nucleus to 
act as donors in the synthesis of sulfo sLex. In order to elucidate the possible 
coregulation of CMP-SA, GDP-Fuc and PAPS transporters, their gene expression  was 
studied by in situ hybridization and qRT-PCR during rat organ allograft rejection. 
Peritubular capillaries in kidney have previously been shown to express sulfo sLex de 
novo, to display lymphocyte-specific adhesion and to display endothelial morphology 
during acute rejection episodes (Kirveskari et al., 2000; Renkonen et al., 1990; 
Turunen et al., 1994). A clear upregulation of transcription of the GDP-Fuc transporter 
was detected three days after transplantation by in situ labeling of kidney cortex and 
outer medulla, the site of leukocyte infiltration during early phases of acute rejection. 
Subsequently, the signal was significantly strong at the corticomedullary junction. At 
day four after transplantation, a strong signal was evenly distributed in the cortex, 
outer medulla and transitional epithelium, after which at the fifth day the signal was 
diminished (Figure 2A/II). The transcription of the transporters were also analyzed in 
rat heart allografts. No signal for GDP-Fuc transporter was evident in control hearts, 
but a specific signal was detected under the epicardium three days after 
transplantation, subsequently, at day four the signal was even stronger, but at day five 
only a low diffuse labeling was detected (Figure 2E/II).  
As with the GDP-Fuc transporter, no signal for the PAPS transporter was detected in 
control kidneys. Three days after transplantation a signal was present in the cortex and 
outer medulla, in the same area where rejection occurred as well as where the GDP-
Fuc transporter signal was induced. The signal was strongest in the corticomedullary 
junction and in the transitional epithelium of the renal pelvis. Four days after 
transplantation both the cortex and inner medulla showed a strong signal for the PAPS 
transporter, which was decreased at day five (Figure 3A/II). In control heart, no PAPS 
transporter signal was detected and only a low signal was seen under the pericardium 
three days after heart transplantation. At day four a moderate signal was evident at the 
right ventricular wall and subsequently, at day five the signal had diminished (Figure 
3E/II). 
The induction of expression of the transporter transcripts were confirmed by qRT-
PCR, which is a more sensitive method than in situ hybridization. All the transporters 
for GDP-Fuc, CMP-SA and PAPS were clearly induced in a time-dependent manner 
during the rejection episodes after kidney transplantation. The expression of all 
transporter transcripts were highest at day three after which they started to decline 
(Figure 4A/II). The expression pattern of transporters in heart allografts were slightly 
different from those in kidney allografts. The transcript levels of transporters increased 
in a time-dependent manner and the expression was highest at day five (Figure 4B/II). 
Allograft rejection in kidney usually affects larger areas of tissue than in heart, which 
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could explain the difference between the levels of expression of the transporter 
mRNAs in kidney and heart. 
Previous results indicated that GDP-Fuc, CMP-SA and PAPS transporters are 
coregulated upon inflammatory stimuli caused by allograft rejection. The expression 
of CMP-SA and GDP-Fuc transporters were further investigated by in silico analysis 
to elucidate whether these genes are coregulated in a large number of experiments 
from various cell types and over a broad range of physiological and experimental 
conditions. Publically available transcriptome data from human gene chip analyses 
containing probes for GDP-Fuc and CMP-SA transporters was used to extract the data 
of interest. The gene chip data indicated that GDP-Fuc and CMP-SA transporters were 
not significantly coregulated under the conditions used in those experiments (Figure 
5/II). Our data, however, suggests that there is a temporospatial induction of GDP-Fuc 
and PAPS transporters and at least a time-dependent induction of the CMP-SA 
transporter at the time the sulfo sLex-dependent leukocyte extravasation begins into 
the sites of tissue inflammation. 
5.3 Rat fucosyltransferase VII (III) 
Rat Fuc-TVII was cloned from rat lymph node by RT-PCR using the sequence details 
of human Fuc-TVII (Lowe et al., 1991). The 3’ end of the sequence was resolved by 
the RACE-PCR method. The two clones isolated, of sizes 2013 and 2100 bp, were 
predicted to encode proteins of 341 and 370 aa, respectively, thus representing two 
splice variants of Fuc-TVII (Figure 1/III). The deduced amino acid sequences 
predicted a classical glycosyltransferase, i.e. a type II transmembrane protein 
composed of a short cytoplasmic tail, a membrane spanning region, a short stem area, 
and a catalytic domain. The sequence had three potential N-glycosylation sites 
whereas the previously cloned human Fuc-TVII had two sites of which both have been 
reported to be occupied (de Vries et al., 2001b). There is evidence that N-glycans of 
fucosyltransferases are required for optimal enzyme activity (Baboval et al., 2000; 
Christensen et al., 2000; Holmes et al., 2000). The cloned rat Fuc-TVII had the α1,3-
Fuc-T motif, FxL/VxFENS/TxxxxYxTEK, a highly conserved stretch of 17 aa´s found 
in α1,3-fucosyltransferases (Martin et al., 1997). It has been speculated that the α1,3-
Fuc-T motif is involved in GDP-L-fucose binding (de Vries et al., 2001a). 
Fuc-TVII activity was analyzed by measuring the radiolabeled GDP-L-fucose 
incorporation to sialylated N-acetyllactosamine in a reaction catalyzed by Fuc-TVII in 
transfected COS-7 cells (Figure 3/III). The specific enzyme activity of the long splice 
variant of Fuc-TVII was high, determined to be 1030 pmol mg-1 h-1, whereas the 
specificity of the short splice variant was the same as the mock control (50 pmol mg-1
h-1). The acceptor specificity was also detected using neutral acceptor substrate. The 
long variant of cloned cDNA showed no α1,3-Fuc-T- activity with the neutral 
acceptor, which was consistent with previous studies of Fuc-TVII, where it acted only 
on sialylated acceptors (Natsuka et al., 1994; Sasaki et al., 1994). When Fuc-TVII 
transfected cells were treated with the N-glycosylation inhibitor tunicamycin, the α1,3-
fucosyltransferase activity was decreased significantly, indicating the requirement of 
N-glycosylation for optimal enzyme activity. Flow cytometric analysis was also used 
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to detect the enzymatic activity of Fuc-TVII in transfected COS-7 cells that express 
endogenously sialylated type 2 glycans (Kukowska-Latallo et al., 1990). COS-7 cells 
transfected with the long splice variant of Fuc-TVII expressed sLex glycans at the cell 
surface, as detected with the anti-sLex monoclonal antibodies (mAb) KM93, CSLEX 
and sLex ab. In contrast to the long splice variant, the short variant and the negative 
vector control showed only minor signal or remained totally negative depending on the 
mAb used (Figure 4/III). Hence, the flow cytometry analysis confirmed the enzyme 
assay results of the long splice variant being the functionally active Fuc-TVII. 
5.4 Gene expression of GDP-L-fucose synthesizing enzymes, GDP-fucose 
transporter and fucosyltransferase VII in inflamed tissues and cancer 
cells (IV) 
The formation of fucosylated glycans depends on the concerted activity of GDP-L-
fucose synthesis and transport into Golgi as well as expression of the appropriate 
fucosyltransferase. The levels of fucosylated epitopes, e.g. sialyl Lewis x, increases 
during the early events of inflammation and in the progress of  cancer (Inaba et al., 
2003; Lowe, 2003). The regulation of gene expression of GDP-L-fucose synthesizing 
enzymes, GDP-fucose transporter and fucosyltransferase VII was studied by qRT-PCR 
in inflamed tissues. Kidney allograft rejection after transplantation between major 
histocompatibility complex-incompatible inbred rat strains was chosen as a model of 
acute inflammation, since de novo expressed sulfo sLex epitopes on the graft 
endothelium have been shown to be crucial in the recruitment of leukocytes to the site 
of inflammation (Kirveskari et al., 2000; Toppila et al., 1999; Turunen et al., 1995). 
The mRNA levels of the enzymes of the de novo pathway of GDP-L-fucose synthesis, 
GDP-fucose transporter and Fuc-TVII were upregulated significantly in kidney 
allografts when compared to normal rat kidney (Figure 3/IV). The upregulation of 
Fuc-TVII in kidney allografts could be detected also by the in situ hybridization assay 
(Figure 6/III). The transcript levels of the enzymes of the salvage pathway were not 
elevated in acute inflammation, suggesting a minor role for them in inflammation 
(Figure 3/IV). 
The gene expression of the same set of enzymes was studied in normal mouse 
endothelial cells and lymphoid tumor cells. Elevated FX expression and increased 
production of GDP-L-fucose have been reported previously in human hepatocellular 
carcinoma (Noda et al., 2003). Our results demonstrated the upregulation of both 
enzymes of the de novo route, FX and GMD, in lymphoid tumor cells as compared to 
non-induced endothelial cells (Figure 2/IV). We subsequently found elevated mRNA 
levels of GDP-fucose transporter and Fuc-TVII in tumor cells, which is consistent with 
the elevated GDP-L-fucose level in cytosol and thus indicates the increased expression 
of fucosylated glycans in tumor cells.  
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6. SUMMARY 
The migration of leukocytes from the blood vessels into inflamed tissue is the essential 
step in the process of inflammation. Binding of leukocytes to the blood vessel wall is 
mediated by cell adhesion molecules and leukocyte-activating factors. Emigration of 
leukocytes from the blood is initiated by the capture of leukocytes from the 
bloodstream followed by their rolling along the endothelial cell surface. The initial 
binding leads to recognition of inflammatory mediators, e.g. chemokines, on 
endothelial cells by leukocytes and subsequently activation of leukocyte integrins. β2-
integrins mediate the tight binding of leukocytes to endothelium by binding to their 
counter-receptors on endothelial cells. Leukocytes diapedese between endothelial cells 
and transmigrate through the endothelial cell layer and the underlying basal membrane 
into the tissue. 
The rolling step is mediated by P-, E- and L-selectins, which bind to their specific 
carbohydrate ligands on proteins or lipids. All selectins recognize a tetrasaccharide 
structure, sialyl Lewis x (sLex), Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc on their 
glycoconjugate ligands. Several glycosyltransferases are involved in the biosynthesis 
of sLex, fucosyltransferase VII (Fuc-TVII) being the last enzyme to modify the sLex 
structure. Fuc-TVII transfers L-fucose from GDP-L-fucose to sialylated N-
acetyllactosamine. GDP-L-fucose is synthesized in the cytosol via two different 
metabolic pathways. The major, constitutively active de novo pathway involves 
conversion of GDP-α-D-mannose to GDP-β-L-fucose. In the alternative “salvage” 
pathway, L-fucokinase synthesizes from free fucose L-fucose-1-phosphate, which is 
further converted to GDP-L-fucose by GDP-L-fucose pyrophosphorylase. GDP-L-
fucose is translocated from the cytosol to Golgi for fucosylation via the GDP-fucose 
transporter.  
This thesis involved the study of the synthesis of GDP-L-fucose via the salvage 
pathway: cloning of the murine L-fucokinase and GDP-L-fucose pyrophosphorylase as 
well as their expression as functional enzymes. Furthermore, the gene expression 
levels of both enzymes were analyzed in various tissues. Golgi transporters involved in 
the synthesis of sulfo sLex, i.e. CMP-SA, GDP-L-Fuc and PAPS transporters, were 
investigated in regard to their transcriptional regulation during inflammation. This 
study also involved the cloning and characterization of rat fucosyltransferase VII, an 
essential enzyme in the formation of sLex. Moreover, the gene expression of GDP-L-
fucose synthesizing enzymes, GDP-fucose transporter and Fuc-TVII was studied in 
acute inflammation and in cancer cells. 
Although the salvage metabolism is the minor pathway of GDP-L-fucose synthesis, L-
fucokinase and GDP-L-fucose pyrophosphorylase are expressed at considerably high 
levels in various tissues. We found the mRNA expression to be highest in brain, ovary, 
testis, and kidney. Nevertheless, these enzymes were not upregulated in acute 
inflammation, nor was their expression significant in cancer cells. Hence, our results 
indicated the salvage pathway of GDP-L-fucose to be irrelevant in tumorigenesis and 
in inflammation. The gene expression of the enzymes of the de novo pathway, GMD 
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and FX, were upregulated significantly in inflammation as well as in cancer cells 
leading to increased amount of GDP-L-fucose in cytosol.  
The mRNA expression level of the GDP-fucose transporter was elevated in inflamed 
tissues as well as in cancer cells, which is consistent with the increased cytosolic GDP-
L-fucose amount. In addition to GDP-fucose transporter, we detected the 
transcriptional regulation of CMP-SA and PAPS transporters in acute inflammation. 
Our results indicate that these transporters have coordinated transcriptional regulation 
during the induction of the sulfo sLex glycan biosynthesis.  
Our results revealed a high gene expression of FUT7 in lymph nodes, which is 
consistent with the constitutive expression of sulfo sLex glycan epitopes in lymph 
node high endothelium and hence their important role in lymphocyte trafficking. In 
non-induced endothelial cells the FUT7 expression was extremely low, but a strong 
upregulation of FUT7 transcripts was detected in acute inflammation as well as in 
cancer cells. Our study indicates that there is transcriptional regulation of GDP-L-
fucose synthesizing enzymes of the de novo pathway, GDP-fucose transporter and 
FUT7, which correlates to the induced expression of sLex glycans in inflammation and 
in tumorigenesis.  
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